[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-intraductal-noninfiltrating\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-intraductal-noninfiltrating":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100557650","phase-2-multimodal-imaging-with-fapi-petmri-in-breast-carcinoma-in-situ-for-detection-of-occult-invasive-cancer-100557650",false,"NCT06540872","Multimodal Imaging With FAPI-PET\u002FMRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer","MI-CISDIR","Inclusion Criteria:\n\n* Newly diagnosed DCIS with extent in mammography, MRI or ultrasound suspected to range \\> 4 cm\n* Planned DCIS resection (breast conserving or mastectomy) as per guideline recommendation\n* Written informed consent\n* For women of child bearing potential: confirmed menstrual period (if applicable) and a negative highly sensitive urine or serum pregnancy test\n* Women of childbearing potential (WOCBP) and male patients with partners of childbearing\u002Freproductive potential must agree to use highly effective contraception (Pearl index \\\u003C 1) when sexually active. This applies for the time period between signing of the informed consent form up to the final trial visit.\n\nExclusion Criteria:\n\n* Contraindications for MRI (specific metallic implants, severe claustrophobia, history of anaphylaxis following MRI contrast agent application)\n* GFR \\\u003C 30 mL\u002F(min∙1.73 m²)\n* Current pregnancy or within last 8 weeks before begin of study participation\n* Current nursing or within last 8 weeks before begin of study participation\n* Inability to understand the nature, risks, and benefits of the study\n* History of diagnosis of ipsilateral invasive breast cancer\n* Concurrent diagnosis of contralateral invasive cancer, if not curatively treated by surgery \\> 1 year ago\n* Known hypersensitivity to the active substance or to any of the excipients of the Investigational Medicinal Product","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET\u002FMRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast cancer in participants with DCIS. The main question it aims to answer is:\n\nHow good can FAPI-PET\u002FMRI diagnose hidden invasive breast cancer in DCIS?\n\nResearchers will compare FAPI-PET\u002FMRI results to tissue samples obtained from surgery treatment to see if the FAPI-PET\u002FMRI images show invasive breast cancer certainly.\n\nParticipants will\n\n* receive the radioactive drug and lie in an imaging device for 45 minutes including a break\n* visit the clinic once again for a checkup and test",[26],"Carcinoma, Intraductal, Noninfiltrating",[28,29,30,31,32],"breast cancer","PET\u002FMRI","DCIS","ductal carcinoma in situ","FAPI","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":37},"2026-02-20",{"date":41,"type":20},"2028-03",{"name":43,"class":44},"Universität Münster","OTHER",2]